Impact of Donor Type on Outcomes After Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: A Study on Behalf of the Chronic Malignancies Working Party of the EBMT

Documenti analoghi

• Methotrexate Versus Mycophenolate Mofetil Prophylaxis in Allogeneic Hematopoietic Cell Transplantation for Chronic Myeloid Malignancies: A Retrospective Analysis on Behalf of the Chronic Malignancies Working Party of the EBMT
  di: Thomas Luft, et al.
  Pubblicazione: (2024)
• Decreased Chronic GvHD With Post‐Transplant Cyclophosphamide Versus ATG in Patients With Myelofibrosis Allografted With an Unrelated Donor: A Study From the Chronic Malignancies Working Party of the EBMT
  di: Yves Chalandon, et al.
  Pubblicazione: (2026)
• Mismatched related donor allogeneic haematopoietic cell transplantation compared to other donor types for Ph+ chronic myeloid leukaemia: A retrospective analysis from the Chronic Malignancies Working Party of the EBMT
  di: Francesco Onida, et al.
  Pubblicazione: (2024)
• Improved post‐transplant outcomes since 2000 for Ph‐positive acute lymphoblastic leukemia in first remission: A study from the EBMT Acute Leukemia Working Party
  di: Ali Bazarbachi, et al.
  Pubblicazione: (2025)
• PTCy or ATG for Matched Transplantation in Myelofibrosis
  di: Patrizia Chiusolo, et al.
  Pubblicazione: (2026)